At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 187 enrolled
Drug / intervention
eftilagimod alpha +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
TACTI-002 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Phase II Study in Patients With Previously Untreated Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC), or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic Squamous Head and Neck Cancer (HNSCC) Receiving the Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) in Combination With Pembrolizumab (PD-1 Antagonist)
In Brief
A Phase 2 clinical trial evaluating eftilagimod alpha and pembrolizumab (KEYTRUDA®) for NSCLC and HNSCC. Completed, enrolled 187 participants across 1 site.
Detailed Summary
Evaluate the safety and efficacy of the combination of eftilagimod alpha with pembrolizumab in non-small cell lung carcinoma and head and neck carcinoma patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartFeb 2019
Primary CompletionJun 2022
Study CompletionNov 2024
TodayJul 2026
First PostedAug 10, 2018
Enrollment StartFeb 21, 2019
Primary CompletionJun 2, 2022
Study CompletionNov 25, 2024
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 7.9 years ago
Interventions
eftilagimod alphadrug
APC activator, MHC II agonist, LAG-3 fusion protein
pembrolizumab (KEYTRUDA®)drug
anti-PD-1 antibody